Pharmaceutical Manufacturing – Live Oral Vaccine Production

The contract involves the manufacture of 18 doses of Live Oral Adenovirus Type 4 and Type 7 Vaccine under current Good Manufacturing Practice standards, ensuring quality, safety, and consistency in production. The work is being performed as a subcontract under the Defense Logistics Agency, part of the Department of Defense, with a NAICS code of 325412 indicating pharmaceutical preparation manufacturing. The vaccine is intended for oral administration and must meet stringent regulatory requirements for live viral biologics. The contract was posted on July 14, 2026, and is linked to a specific delivery order under a larger procurement referenced by the contract number SPE2DP20D0002 and delivery order SPE2DP26F7506. While specific location details for performance or point of contact are not provided, the production must occur in a facility compliant with cGMP to ensure the vaccine meets federal and military health standards.